Skip to content

Depreciation at other companies

Revvity logo
RevvityRVTY
Gilead Sciences logo
Gilead SciencesGILD
Biogen logo
BiogenBIIB
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Insmed logo
InsmedINSM
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s depreciation?
Krystal Biotech, Inc. (KRYS) reported depreciation of $1.52M in Q1 2026.
How has Krystal Biotech, Inc.'s depreciation changed year-over-year?
Krystal Biotech, Inc.'s depreciation increased by 7.9% year-over-year, from $1.41M to $1.52M.
What is the long-term trend for Krystal Biotech, Inc.'s depreciation?
Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s depreciation has grown at a 32.3% compound annual growth rate (CAGR), from $1.85M to $5.67M.